PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
PDS Biotechnology Co. (NASDAQ: PDSB) had its price target lowered by analysts at HC Wainwright from $21.00 to $13.00. They now have a "buy" rating on the stock.
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]